(redirected from Immune rejection)
Also found in: Dictionary, Thesaurus, Medical, Legal, Financial.
Related to Immune rejection: Organ rejection


Destruction of a graft by the immune system of the recipient.

What does it mean when you dream about a rejection?

Rejection in a dream may suggest that there are feelings or situations the dreamer wants to be rid of.

References in periodicals archive ?
The researchers discovered that the combination of these two molecules allowed the allogeneic cells to survive in humanized mice without triggering an immune rejection.
In December 1998, Harold Varmus, then head of the National Institutes of Health, acknowledged during Senate testimony that immune rejection had to be overcome before stem cells could be used for transplantation, but he suggested that we might be able to do so without resorting to autologous stem cell transplantation.
If hESC-derived hematopoietic cells prove to be a scalable way to prevent immune rejection, this will certainly benefit our approach, and could obviate the scientific rationale for patient-specific therapies that are based on adult stem cells or nuclear transfer.
There is a second technology for obtaining stem cells, one that has neither the problem of immune rejection in its future, nor -- in my opinion at any rate - the taint of a lost soul in its design.
Immune rejection is mediated by our genetic makeup, specifically the set of genes which code for a type of protein called human leukocyte antigens (HLA).
To avoid the problems of immune rejection, scientists might establish a bank of human embryonic stem cells that would match almost anyone in the population.
4) The prevention of immune rejection of transplanted cells.
There is no fully effective treatment for the conditions but the transfer to the patient of "clean cells" of their own type would ensure there would be no immune rejection.
Because animals like pigs are quite different from humans, their organs would probably trigger a very strong immune rejection.
ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation.
The study, conducted by scientists at the University of California, San Francisco (UCSF) and ViaCyte, a privately-held regenerative medicine company, documented in a mouse model that a selective blockade of specific elements of the immune system, co-stimulatory blocking agents CTLA4Ig and anti-CD154, allows the implanted precursor cells to avoid immune rejection and develop into the insulin-producing and other cells of the healthy endocrine pancreas.
Marolt hopes to develop personalized bone grafts that will avoid immune rejection and other implant complications.